<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893358</url>
  </required_header>
  <id_info>
    <org_study_id>ANTI-MASK20160830</org_study_id>
    <nct_id>NCT02893358</nct_id>
  </id_info>
  <brief_title>Antihypertensive Treatment in Masked Hypertension for Target Organ Protection</brief_title>
  <acronym>ANTI-MASK</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Yan Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute of Hypertension</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to estimate the target organ protection after 12 months
      of antihypertensive treatment in masked hypertension patients with at least one kind of
      target organ damage (left ventricular hypertrophy, large arterial stiffness and
      microalbuminuria). Improvement was defined as the relevant parameter back to normal or
      declined at least 20%.

      The secondary objectives include: blood pressure lowering effect, target organ damage
      parameters improvement, and the incidence rate of all cause death and cardiovascular events
      (stroke and myocardia infraction).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria)</measure>
    <time_frame>1 year</time_frame>
    <description>Improvement was defined as the relevant parameters (Cornell voltage combination, Sokolow-Lyon index, microalbuminuria/creatinine ratio, brachial-ankle pulse wave velocity) back to normal or declined at least 20%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h ambulatory blood pressure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>1 year</time_frame>
    <description>calculating Cornell voltage combination and Sokolow-Lyon index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microalbuminuria/creatinine ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brachial-ankle pulse wave velocity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Masked Hypertension</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP&lt;130/80 mmHg, and daytime BP &lt;135/85 mmHg, and nighttime BP &lt;120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets are identical to the active study drugs, with a similar schedule of administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allisartan Isoproxil</intervention_name>
    <description>Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 30-70 years old

          2. Masked hypertension patients, defined as clinic BP&lt;140/90 mmHg, while 24h ambulatory
             BP ≥130/80 mmHg and (or) daytime BP ≥135/85 mmHg and (or) nighttime BP ≥120/70 mmHg

          3. Combined with at least one kind of target organ damage: left ventricular hypertrophy
             (Cornell voltage combination ≥2440mm·ms or Sokolow-Lyon index ≥4.0mv for male and
             3.5mv for female), large arterial stiffness (brachial-ankle pulse wave velocity
             ≥1400cm/s) and microalbuminuria (twice random urine microalbuminuria/creatinine ratio
             ≥2.5mg/mmol for male and 3.5mg/mmol for female).

          4. Didn't use any anti-hypertension drugs within 2 weeks

          5. Be willing to participate in the trials and able to finish clinic visits

        Exclusion Criteria:

          1. Under antihypertensive treatment

          2. Secondary hypertension

          3. Taking other medications that may influence BP

          4. Sleep apnea syndrome

          5. Diabetes combined with microalbuminuria

          6. Renal parenchymal disease, such as chronic nephritis, polycystic kidney

          7. Occurrence of coronary heart disease, myocardial infraction or stroke within 6 months

          8. Structural heart disease, such as hypertrophic cardiomyopathy, dilated cardiomyopathy

          9. Alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) upper
             the twice of normal range, serum creatinine (Scr)≥2.0mg/dl, plasma
             hypokalemia≥5.5mmol/L,

         10. Patients have contraindications to angiotensin receptor blockers (ARBs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Li, Professor</last_name>
    <phone>021-64370045</phone>
    <phone_ext>663228</phone_ext>
    <email>liyanshcn@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Li, Professor</last_name>
      <phone>021-64370045</phone>
      <phone_ext>663228</phone_ext>
      <email>liyanshcn@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yan Li, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Institute of Hypertension</investigator_affiliation>
    <investigator_full_name>Yan Li</investigator_full_name>
    <investigator_title>Professor, Doctor of Medicine, Doctor of Philosophy</investigator_title>
  </responsible_party>
  <keyword>Allisartan Isoproxil</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>large arterial stiffness</keyword>
  <keyword>microalbuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Masked Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

